Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Forum of Clinical Oncology
AHEAD OF PRINT
Open Access
Change of dosing paradigm in oncology
Sophia Papakatsika
Sophia Papakatsika
,
Myrsini Orfanidou
Myrsini Orfanidou
,
Elpiniki Rentzeperi
Elpiniki Rentzeperi
and
Christos Emmanouilides
Christos Emmanouilides
| May 20, 2024
Forum of Clinical Oncology
AHEAD OF PRINT
About this article
Previous Article
Next Article
Abstract
Article
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research Article
Published Online:
May 20, 2024
Page range:
-
Received:
Apr 27, 2023
Accepted:
Dec 22, 2023
DOI:
https://doi.org/10.2478/fco-2023-0022
Keywords
Chemotherapy dosing
,
MTD
,
novel therapies
,
monoclonal antibodies
,
sotorasib
© 2023 Sophia Papakatsika et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Sophia Papakatsika
Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia
Greece
Myrsini Orfanidou
Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia
Greece
Elpiniki Rentzeperi
Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia
Greece
Christos Emmanouilides
Oncology Department, Interbalkan Medical Center, Pylaia, Central Macedonia
Greece